Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier , Montpellier, France.
Expert Rev Mol Diagn. 2020 Sep;20(9):913-919. doi: 10.1080/14737159.2020.1816828. Epub 2020 Sep 3.
Breast cancer is the most common cancer in women worldwide. Despite the development of targeted therapies that have significantly improved survival, effective breast cancer evaluation is still challenging due to the complexity of this disease. Liquid biopsy might allow the noninvasive real-time monitoring of the tumor course and response to therapy.
This review summarizes the latest advances on the various circulating analytes used as liquid biopsy (circulating tumor cells and tumor DNA, and more recently extracellular vesicles) for breast cancer work-up. Several studies have shown that in breast cancer, liquid biopsy can be used to predict disease progression or relapse and to monitor the treatment response. Moreover, circulating analytes are more easily accessible than tissue biopsies and might represent a powerful source of specific knowledge.
The new evidence coming from the increasing number of clinical trials, and the continuous improvements in the technologies to isolate these tumor-derived analytes should strengthen the role of liquid biopsy in the clinic for personalized medicine of breast cancer.
乳腺癌是全球女性最常见的癌症。尽管靶向治疗的发展显著提高了生存率，但由于这种疾病的复杂性，有效的乳腺癌评估仍然具有挑战性。液体活检可能允许对肿瘤过程和对治疗的反应进行非侵入性的实时监测。
这篇综述总结了最新的进展，涉及作为液体活检（循环肿瘤细胞和肿瘤 DNA，以及最近的细胞外囊泡）用于乳腺癌评估的各种循环分析物。多项研究表明，在乳腺癌中，液体活检可用于预测疾病进展或复发，并监测治疗反应。此外，循环分析物比组织活检更容易获得，并且可能代表了特定知识的有力来源。
越来越多的临床试验带来的新证据，以及分离这些肿瘤衍生分析物的技术的不断改进，应该会加强液体活检在乳腺癌个体化医学临床中的作用。
